

# World Journal of *Radiology*

*World J Radiol* 2019 September 28; 11(9): 116-125



**CASE REPORT**

- 116 Metastatic appendiceal cancer treated with Yttrium 90 radioembolization and systemic chemotherapy: A case report

*Bhat AP, Schuchardt PA, Bhat R, Davis RM, Singh S*

**ABOUT COVER**

Editorial Board Member of *World Journal of Radiology*. Irmak Durur-Subasi, MD, PhD, Associate Professor, Department of Radiology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara 06110, Turkey

**AIMS AND SCOPE**

The primary aim of *World Journal of Radiology (WJR, World J Radiol)* is to provide scholars and readers from various fields of radiology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJR* mainly publishes articles reporting research results and findings obtained in the field of radiology and covering a wide range of topics including state of the art information on cardiopulmonary imaging, gastrointestinal imaging, genitourinary imaging, musculoskeletal imaging, neuroradiology/head and neck imaging, nuclear medicine and molecular imaging, pediatric imaging, vascular and interventional radiology, and women's imaging.

**INDEXING/ABSTRACTING**

The *WJR* is now abstracted and indexed in Emerging Sources Citation Index (Web of Science), PubMed, PubMed Central, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (CSTJ), and Superstar Journals Database.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Responsible Electronic Editor: *Mei-Yi Liu*  
 Proofing Production Department Director: *Xiang Li*

**NAME OF JOURNAL**

*World Journal of Radiology*

**ISSN**

ISSN 1949-8470 (online)

**LAUNCH DATE**

January 31, 2009

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Venkatesh Mani

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1949-8470/editorialboard.htm>

**EDITORIAL OFFICE**

Ruo-Yu Ma, Director

**PUBLICATION DATE**

September 28, 2019

**COPYRIGHT**

© 2019 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Metastatic appendiceal cancer treated with Yttrium 90 radioembolization and systemic chemotherapy: A case report

Ambarish P Bhat, Philip A Schuchardt, Roopa Bhat, Ryan M Davis, Sindhu Singh

**ORCID number:** Ambarish P Bhat (0000-0002-8628-7465); Philip A Schuchardt (0000-0002-3090-687X); Roopa Bhat (0000-0002-7772-2509); Ryan M Davis (0000-0002-0858-3330); Sindhu Singh (0000-0003-4125-1693).

**Author contributions:** Bhat AP planned and performed the Y90 radioembolization, wrote the paper, and responded to edits from both the University of Missouri care team and publication editors. Schuchardt PA wrote the paper and participated in the editing process. Bhat R wrote the paper and participated in the editing process. Davis RM planned and performed the Y90 radioembolization and participated in the editing process. Singh S prescribed the patient's chemotherapy and provided advice regarding recommended treatments.

**Informed consent statement:** Informed consent was obtained from the patient.

**Conflict-of-interest statement:** No conflict of interest declared.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0)

**Ambarish P Bhat, Philip A Schuchardt, Roopa Bhat, Ryan M Davis,** Department of Vascular and Interventional Radiology, University of Missouri Columbia, Columbia, MO 65212, United States

**Sindhu Singh,** Department of Medicine, Section of Hematology-Oncology, University of Missouri-Columbia, Columbia, MO 65212, United States

**Corresponding author:** Ambarish P Bhat, MD, Assistant Professor, Department of Vascular and Interventional Radiology, University of Missouri Columbia, One Hospital Drive, Columbia, MO 65212, United States. [bhatap@health.missouri.edu](mailto:bhatap@health.missouri.edu)

**Telephone:** +1-573-8821025

**Fax:** +1-573-8844457

### Abstract

#### BACKGROUND

Primary appendiceal cancers are rare, and they generally present with liver and/or peritoneal metastases. Currently there are no guidelines to treat metastatic appendiceal cancer, and hence they are treated as metastatic colorectal cancer. Combining Yttrium 90 (Y-90) radioembolization (RE) with systemic chemotherapy early in the treatment of right sided colon cancers has been shown to improve survival. Based on this data, a combination of systemic chemotherapy and Y-90 RE was used to treat a case of metastatic appendiceal cancer.

#### CASE SUMMARY

A 76-year-old male presented to the emergency room with progressive right lower quadrant pain. A Computed Tomography of the abdomen and pelvis was performed which showed acute appendicitis and contained perforation. Urgent laparoscopic appendectomy was then followed by histological analysis, which was significant for appendiceal adenocarcinoma. After complete workup he underwent right hemicolectomy and lymph node dissection. He received adjuvant chemotherapy as the local lymph nodes were positive. Follow-up imaging was significant for liver metastasis. Due to rapid growth of the liver lesions and new peritoneal nodules, the patient was treated with a combination of Y-90 RE and folinic acid, fluorouracil, and irinotecan with bevacizumab and not microwave ablation as previously planned. Follow up imaging demonstrated complete response of the liver lesions. At 12-mo follow-up, the patient continued to enjoy good quality of life with no recurrent disease.

#### CONCLUSION

Utilization of Y-90 RE concomitantly with systemic chemotherapy early in the

license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Received:** March 2, 2019

**Peer-review started:** March 4, 2019

**First decision:** August 2, 2019

**Revised:** August 10, 2019

**Accepted:** August 21, 2019

**Article in press:** August 21, 2019

**Published online:** September 28, 2019

**P-Reviewer:** Bazeed MF, Gavriilidis P

**S-Editor:** Ma RY

**L-Editor:** A

**E-Editor:** Liu MY



treatment of appendiceal cancer may provide improved control of this otherwise aggressive cancer.

**Key words:** Colorectal cancer; Liver metastases; Radioembolization; Yttrium 90 microspheres; Appendix cancer with peritoneal metastasis; Hyperthermic intraperitoneal chemotherapy; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Primary appendiceal cancers are rare and there are no current guidelines for treatment of metastatic appendiceal cancer. We describe an unusual case of appendiceal cancer metastatic to the liver and peritoneum that was successfully treated with a combination of systemic chemotherapy and Yttrium 90 radioembolization. This complete and sustained response may support a role for combination therapy in the more aggressive right sided colon cancers.

**Citation:** Bhat AP, Schuchardt PA, Bhat R, Davis RM, Singh S. Metastatic appendiceal cancer treated with Yttrium 90 radioembolization and systemic chemotherapy: A case report. *World J Radiol* 2019; 11(9): 116-125

**URL:** <https://www.wjnet.com/1949-8470/full/v11/i9/116.htm>

**DOI:** <https://dx.doi.org/10.4329/wjr.v11.i9.116>

## INTRODUCTION

Primary cancers of the appendix are rare and often aggressive. There are no evidence based guidelines to deal with patients who present with aggressive metastatic appendiceal cancers. Surgical cytoreduction and hyperthermic intraoperative chemotherapy (HIPEC) have shown survival benefit in some patients<sup>[1]</sup>. However, it is a rather extensive and major operation and not suitable for all patients. In patients who are not suitable candidates, there are very limited options and hence, they have a dismal prognosis. In the past decade, the role of Yttrium 90 (Y-90) radioembolization (RE) in chemorefractory metastatic colorectal cancer (CRC) has been extensively studied and has produced promising results<sup>[2-4]</sup>. Due to its proven synergistic role with systemic chemotherapy, a combination of Y-90 RE and chemotherapy was used to successfully treat a patient with metastatic appendiceal cancer.

## CASE PRESENTATION

### Chief complaints

A 76-year-old male initially presented to the emergency room with progressive pain in the right lower quadrant.

### History of present illness

The pain was localized to the right lower quadrant without any radiation. The pain was associated with anorexia, without nausea or vomiting. Low grade fever was present.

### History of past illness

Significant for hypertension controlled with medications and benign prostatic hyperplasia.

### Personal and family history

No history of alcohol, or drug abuse.

### Physical exam upon admission

Vital signs: Heart rate 108/min, respiratory rate 23/min, BP 130/82 mmHg. Temperature: 37.1 °C.

Cardiovascular: Tachycardia with normal heart sounds.

Respiratory: Normal breath sounds.

Abdomen: Moderate tenderness in the right lower quadrant. No abdominal

distension. Normal bowel sounds. Neurological: Alert, oriented, without neurological deficits.

### **Laboratory examinations**

The blood work showed leukocytosis, with white blood cell:  $12 \times 10^9$  L. The rest of the labs were normal.

### **Imaging examinations**

Contrast-enhanced computed tomography (CT) of the abdomen and pelvis demonstrated a markedly dilated appendix with surrounding inflammatory changes (Figure 1) and regional lymphadenopathy. This was originally interpreted as acute appendicitis with contained perforation.

---

## **TREATMENT**

The patient then underwent urgent laparoscopic appendectomy and drainage of the intra-abdominal abscess. Pathology of the surgical specimen revealed a moderately differentiated appendiceal adenocarcinoma, measuring 1.7 cm, with tumor invading the mesoappendix. Extensive transmural inflammatory changes were noted, though the base of the appendix was not involved. The patient underwent colonoscopy to excluded synchronous lesions. As the colonoscopy was negative for additional lesions, the patient subsequently underwent laparoscopic right hemicolectomy with primary anastomosis and lymph node dissection. During the operation the rest of the abdomen was thoroughly inspected for metastatic disease. After performing laparoscopic right hemicolectomy with primary anastomosis and lymph node dissection, histopathology demonstrated 6/18 lymph nodes positive for metastatic adenocarcinoma with extra-nodal extension present in the largest lymph node. The distal ileum and cecum were free of malignancy. The staging was completed by obtaining a CT of the chest (as it had not been obtained in the initial presentation), and it showed no evidence of metastatic disease.

The patient then received 12 cycles of adjuvant folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy for a duration of 7 mo from the initial diagnosis. Follow-up CT 10 mo after the last cycle of chemotherapy demonstrated three hypodense hypovascular lesions in the right lobe of the liver (two in segment 7 and one in segment 2) (Figure 2) with concurrent rise in serum carcinoembryonic antigen level. Ultrasound guided biopsy of the liver lesions revealed metastatic adenocarcinoma, consistent with an appendiceal primary.

---

## **FINAL DIAGNOSIS**

Final diagnosis was stage IIIC (T3, N2, Mx) moderately differentiated appendiceal adenocarcinoma.

---

## **MULTIDISCIPLINARY EXPERT CONSULTATION**

Due to the complexity of the case. It was presented at the multidisciplinary tumor board and a decision was made to proceed with microwave ablation of the liver lesions. Fluorodeoxyglucose (FDG) positron emission tomography (PET) CT obtained prior to microwave ablation demonstrated an increase in the size of the liver lesions (FDG avid) and new sub-centimeter FDG avid lesions in the peritoneum, suggestive of metastatic implants (Figure 3). Two of the three lesions, now measured more than 3 cm, prompting us to hold off on the microwave ablation. The patient was again presented to the multidisciplinary tumor board and was not considered a surgical candidate for hepatic metastasectomy or HIPEC due to general deconditioning, including severe weight loss. In light of the progressive hepatic and limited extrahepatic disease burden, the patient was offered selective internal radiation treatment or RE with Y90 and initiation of folinic acid, fluorouracil, and irinotecan (FOLFIRI) with bevacizumab, as a palliative measure. FOLFIRI was initiated prior to the Y-90 RE procedure; however, the bevacizumab was not started until after the RE procedure.

A mapping angiogram was performed one week prior to the Y-90 RE treatment to evaluate the vascular anatomy and estimate the lung shunt fraction (LSF). As a part of the mapping angiogram, the gastroduodenal artery was embolized using 4 and 5 mm 0.018" Azur® CX coils (Terumo Interventional Systems). Based on the planar images



**Figure 1** Axial and coronal abdominal contrast enhanced computed tomography images depict a fluid filled and dilated appendix (gray arrows) and adenopathy (white arrow). Surrounding inflammatory changes present.

obtained after injection of  $^{99m}\text{Tc}$ -labeled macroaggregated albumin ( $^{99m}\text{TcMAA}$ ) into the right hepatic artery, the shunt fraction toward the lung was calculated at approximately 2.5%.

Calculations of liver and tumor volumes were performed on a 3D segmentation application (TeraRecon Inc Foster City, CA, United States). The whole liver volume was 1325 mL. The right lobe measured 875 mL, the tumor volume was 150 mL, and the tumor to normal liver ratio (T:N) based off the  $^{99m}\text{TcMAA}$  injection during the mapping angiogram was 3:1. The prescribed activity was calculated using the DAVYR application (Dose and activity visualizer for Y-90 RE) (Figure 4) and the SIR sphere microsphere activity calculator (SMAC) chart provided by the manufacturer and a 1.0 Gigabecquerel (Gq) activity of Y90 was prescribed for treatment of the right lobe metastatic lesions. Based on the body surface area (BSA) method recommended by the manufacturer, the dose to the tumor was estimated as 126 Gray (Gy) and dose to the healthy liver was estimated at 40.9 Gray (Gy) (Figure 4). The prescribed activity was successfully administered by positioning a Progreat 2.8 F 130 cm catheter (Terumo Interventional Systems) in the right hepatic artery distal to the origin of the cystic artery (Figure 5). Post procedure Bremsstrahlung planar and single photon emission computed tomography (SPECT) demonstrated appropriate distribution of Y90 spheres in the hepatic lobe without evidence of non-target embolization (Figure 6).

## OUTCOME AND FOLLOW-UP

Post RE FDG PET/CT performed two months after treatment (Figure 7) showed complete response, with no residual FDG-avid lesions in the liver or peritoneum. No new lesions were identified. At this point, based on the good response to treatment, the oncologist switched him to a combination of oral capecitabine and bevacizumab. The patient has been followed for 12 mo after the Y-90 treatment and continues to demonstrate good quality of life with no recurrent disease. There were no significant changes to his liver functions after treatment, except slight elevation of his alkaline phosphatase. The only toxicity was hyperpigmentation of the fingers and oral ulcers (hand foot mouth disease) which started 10 mo into the treatment and resolved with reduction of the capecitabine dose.

## DISCUSSION

The incidence of appendiceal cancer is 1.2 per 100000 people per year in the United States. Potentially due in part to this rarity, there are no accepted American Joint Commission on Cancer staging system or National Comprehensive Cancer Network evidence-based guidelines recommended for appendiceal cancer<sup>[5]</sup>. Colon cancer workup, staging, and treatment is commonly applied to appendiceal carcinoma.

Appendiceal cancers can either present with or progress to peritoneal dissemination and the optimal therapy is complete surgical cytoreduction in combination with HIPEC<sup>[6]</sup>. For patients not eligible for complete cytoreduction and HIPEC, as in this case, systemic chemotherapy with regimens utilized for metastatic CRC are generally considered the mainstay therapy. We embarked on a literature review to find potential treatment options for our patient.

A systematic review of the literature was performed using Pubmed for articles from




Figure 2 Axial sequential abdominal contrast enhanced computed tomography images (A-C) depict 3 new hepatic lesions in the right lobe (white arrows).


inception to January 2019 using the key words “Y90”, “metastatic Appendix cancer” and “systemic chemotherapy”. We did not find any studies in which Y-90 RE was used to treat liver metastasis form appendix cancer. However we found several studies using Y 90 in the salvage setting following failure of chemotherapy with improved overall survival numbers<sup>[2-4]</sup>. Data was extracted by two extractors.

Interventional oncology treatments for liver dominant CRC metastasis include, RE, drug eluting beads irinotecan (DEBIRI) transarterial chemoembolization (TACE) and thermal ablation.

RE with Y-90 microspheres is based on the same principle as that of TACE, in that the hepatic artery provides the primary vascular supply to the tumor, while the portal vein provides the majority of blood flow to normal hepatic parenchyma<sup>[7]</sup>. Furthermore, the microvascular density of hepatic tumors is much higher than the hepatic parenchyma<sup>[8]</sup>, resulting in a proportionately higher exposure to microspheres. CRC cells are highly radiosensitive and even chemo-refractive lesions do not generally demonstrate any cross-resistance to radiation. Additionally, radiation works synergistically when used with radiation-sensitizing chemotherapeutic drugs.

The two commercial manufacturers of Y-90 microspheres are TheraSpheres (BTG International, ON, Canada) and SIR-spheres (Sirtex Medical Inc., Sydney, Australia). These microspheres, that have been specifically developed to deliver Y-90, measure 20-60  $\mu\text{m}$  in size. Y-90 primarily emits beta radiation, with a half-life of 64.1 h and an average energy of 0.94 MeV. The beta particles have a range of 1.1 cm (average 2.5 mm *in vivo*) from the source, with 94% of the dose being deposited within the first 11 d of administration<sup>[9]</sup>. Hence, RE works from “inside out” and inflicts minimal damage to the normal liver. This is in contrast to external beam radiation which exposes the normal liver parenchyma to excessive amounts of radiation, in the process of killing multifocal tumors, thus increasing collateral damage. One of the most critical components of the RE procedure is the dosimetry. There is one activity calculation method for Y-90 glass microspheres<sup>[10]</sup>, however three alternatives exist for resin microspheres<sup>[11-13]</sup>.

Both liver and tumor volumes, calculated based on CT or magnetic resonance imaging are used to determine resin microsphere activity. The empiric model recommends administration of 2.0 GBq for < 25% involvement, 2.5 GBq for 25%-50% involvement, and 3.0 GBq for > 50% involvement<sup>[13]</sup>. This method has low safety



**Figure 3** Coronal and axial fluorodeoxyglucose positron emission tomography images show fluorodeoxyglucose avid liver (white arrows) and peritoneal (black arrows) metastases.

margins<sup>[13,14]</sup> and is generally not recommended. The empiric method adjusted for patient BSA has been more widely utilized to calculate the activity needed to treat liver tumors<sup>[12]</sup>. This model assumes that the patient's BSA is proportional to liver volume, thus leading to a method of dose adjustment. Activity in GBq =  $(BSA - 0.2) + [V_{\text{Tumor}} / (V_{\text{Tumor}} + V_{\text{Liver}})]$ . Where  $V_{\text{Tumor}}$  is the tumor volume and  $V_{\text{Liver}}$  is liver volume<sup>[12]</sup>.

Lastly, the partition model is the only calculation method predicated on Medical Internal Radiation Dose principles (MIRD)<sup>[15-17]</sup>. The partition model identifies the lungs, tumor, and uninvolved liver parenchyma as three distinct vascular compartments that can be partitioned during RE<sup>[15]</sup> and the dose to the individual components can be estimated for optimization and safety of the procedure. A slightly simplified MIRD based equation calculates the dose to the liver as follows: D liver (Gy) = Injected activity (GBq)  $\times$  50  $\times$  fractional uptake liver  $\times$  [m liver (kg)] - 1.

With fractional uptake (FU) of the liver defined as:  $FU_{\text{liver}} = (1 - LSF) [m_{\text{liver}} / TLR \times m_{\text{tumor}} + m_{\text{liver}}]$ , where  $m_{\text{liver}}$  is the liver mass, TLR is tumor to liver ratio and LSF is LSF.

This model usually works well with discrete tumor that can be separated from the surrounding parenchyma (generally hepatocellular cancer). The BSA activity planning is suited for small lesions with diffuse or infiltrative margins, which cannot be separated from the uninvolved liver parenchyma (generally metastasis).


A tumoricidal dose for SIR spheres is considered to be 120 Gy, so little benefit is gained when exceeding this dose, while parenchymal damage continues to increase with larger radiation doses<sup>[18,19]</sup>. The dose for uninvolved, normal parenchyma should preferably be at 50 Gy and should never exceed 70 Gy.

For TheraSphere<sup>®</sup> noncompartmental MIRD macrodosimetry proposed for by Salem *et al*<sup>[11]</sup> is used. It uses the following equation for computation of the activity and assumes Y 90 distributes uniformly within the liver and decays completely *in situ*. Activity required (GBq) = [desired dose (Gy)]  $\times$  [target liver mass (kg)]/50.

Of note, Therasphere dosimetry is independent of the tumor volume and depends solely on the infused tissue mass. For Therasphere, the recommended mean absorbed is between 80 and 150 Gy per lobe<sup>[11]</sup>. The recommended tumoricidal doses is 120 Gy for HCC (due to the underlying cirrhosis) and 150 Gy for metastases<sup>[11]</sup>. Maximum exposure to the lungs should be less than 30 Gy per session and 50 Gy cumulatively<sup>[17]</sup>. Both manufacturers recommend prescribed activity reductions for patients with lung shunts higher than 10%<sup>[10,13]</sup>.

Several investigators have studied the application of Y-90 RE in the salvage setting for liver dominant metastatic CRC<sup>[2,3]</sup>. Van Hazel *et al*<sup>[4]</sup> reported results of combined Y-90 RE with systemic irinotecan therapy in patients who failed initial 5-FU chemotherapy. In a group of 25 patients, 11 (48%) had partial response (PR) and 9 (39%) had stable disease. Median survival was 12.2 mo.

DEBIRI TACE has been proposed by some as a possible alternative to RE, however evidence within the literature is currently limited. In our institute we consider it in cases where Y-90 RE is contraindicated or in the setting of failed RE therapy. TACE



**Figure 4** Dose and activity visualizer for Yttrium-90 radioembolization (DAVYR) application chart obtained after inputting the necessary fields, displaying the medical internal radiation dose, body surface area and partition models with prescribed activity Gigabecquerel, estimated dose to the tumor, liver and lungs Gray.


with DEBIRI involves two separate treatment sessions for each lobe, with each session occurring 4 wk apart<sup>[20]</sup>. Based on this, patients with bilobar disease, may need four procedures. During each treatment session, as much as one vial of 100- to 300- $\mu$ m LC Beads (Biocompatibles, Oxford, CT) loaded with 100-mg irinotecan is selectively delivered to treat the hepatic lesions. Furthermore, post-embolization syndrome is more severe after DEBERI as compared to Y-90, with moderate to severe abdominal pain observed in up to 30% of treatment sessions<sup>[20,21]</sup>.

Thermal ablation has been successfully used in treatment of non resectable CRC liver metastasis, with best outcomes for isolated liver lesions less than 3 cm without systemic spread<sup>[22]</sup>. Although our patient initially appeared to be a good candidate for thermal ablation, his staging PET showed increased in size of the hepatic lesions and new lesions in the peritoneum, making him a less suitable candidate for liver ablation alone and prompted us to use systemic therapy and more aggressive liver directed therapy in the form of Y-90 RE to the right lobe.

Several studies in the past 2 years have reported that patients have worse survival outcomes with right sided colon cancer, and they may benefit less from standard therapies<sup>[23,24]</sup>. The subset of patients with right sided tumors in the SIRFLOX, FOXFIRE and SIRFLOX global trials had a better overall survival from addition of RE in combination with first line chemotherapy<sup>[25]</sup>. Gene expression analyses have identified 4 consensus molecular subtypes (CMSs) which are different with right and left-sided CRCs, with greater proportions of the “microsatellite unstable/immune” CMS1 and the “metabolic” CMS3 subtypes found in right-sided colon cancers<sup>[26]</sup>, which may explain their different behavior and natural history.


## CONCLUSION

To the best of our knowledge, this is the first report of Y-90 RE used with systemic chemotherapy to treat hepatic metastatic disease from appendiceal cancer. The aggressive disease progression demonstrated in this case appears to mirror the aggressiveness one might see from typical right sided colonic malignancies. Most studies using Y90 RE in the salvage setting report PR of liver lesions. The patient in this case report had a complete response of both liver and peritoneal metastases presumably form a combination of Y-90 RE and systemic chemotherapy. The relative contribution of the two individual treatments or any possible synergy between the treatments is unknown, however initiating Y-90 RE early in the treatment may have contributed to the excellent control of what was otherwise a rapidly progressive




**Figure 5 Hepatic angiogram.** Yttrium 90 administration to the right lobe. The tip of the catheter (purple arrow) is at the bifurcation of the sectoral branches of the right hepatic artery. Coils in the gastro-duodenal artery (yellow arrow).

cancer. More studies are needed to assess the benefit of adding Y-90 RE to chemotherapy treatments early in the course of appendiceal/right sided colon cancers.



**Figure 6** Axial post procedure single photon emission tomography image shows appropriate distribution of Yttrium 90 particles in the right hepatic lobe with increased focal uptake in one of the right lobe lesions (white arrow).



**Figure 7** A restaging skull base to mid-thigh fluorodeoxyglucose positron emission tomography/computed tomography scan was performed after injection of 4.9 mCi of fluridexoyglucose 2 mo following Yttrium 90 radioembolization. The post Yttrium 90 treatment positron emission tomography (PET) maximum intensity projection (MIP) coronal (A), attenuation corrected axial (B) and fused axial (C) PET images show complete resolution of all lesions with focal photopenia in the right hepatic lobe (white arrowheads). Incidentally, there is chemotherapy induced diffuse skeletal uptake and a small urinary bladder diverticulum (purple straight arrow A). The pre-therapy Positron emission tomography images are provided for comparison. Coronal MIP image (D) axial attenuation correction (E), and fused axial (F). Pretreatment PET images show multiple fluridexoyglucose avid right lobe hepatic (white arrows) and peritoneal (black arrows) lesions. PET: Positron emission tomography; MIP: Maximum intensity projection.

## REFERENCES

- 1 Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 2003; **21**: 3737-3743 [PMID: 14551293 DOI: 10.1200/JCO.2003.04.187]
- 2 Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITIO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. *Br J Cancer* 2010; **103**: 324-331 [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770]
- 3 Bester L, Meteling B, Pocock N, Pavlakis N, Chua TC, Saxena A, Morris DL. Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and

- adverse events in salvage patients. *J Vasc Interv Radiol* 2012; **23**: 96-105 [PMID: 22079516 DOI: 10.1016/j.jvir.2011.09.028]
- 4 **van Hazel GA**, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D, Bower GD, Briggs GM, Rossleigh MA, Taylor DJ, George J. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. *J Clin Oncol* 2009; **27**: 4089-4095 [PMID: 19652069 DOI: 10.1200/JCO.2008.20.8116]
- 5 **McCusker ME**, Coté TR, Clegg LX, Sobin LH. Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. *Cancer* 2002; **94**: 3307-3312 [PMID: 12115365 DOI: 10.1002/cncr.10589]
- 6 **Sugarbaker PH**, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. *Dis Colon Rectum* 1993; **36**: 323-329 [PMID: 8458256 DOI: 10.1007/BF02053933]
- 7 **Breedis C**, Young G. The blood supply of neoplasms in the liver. *Am J Pathol* 1954; **30**: 969-977 [PMID: 13197542]
- 8 **Lien WM**, Ackerman NB. The blood supply of experimental liver metastases. II. A microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber. *Surgery* 1970; **68**: 334-340 [PMID: 5450714]
- 9 **Kalva SP**, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. *Radiographics* 2008; **28**: 101-117 [PMID: 18203933 DOI: 10.1148/rg.281075115]
- 10 Package Insert-TheraSphere® Yttrium-90 Glass Microspheres. Available from: <http://www.therasphere.com>
- 11 **Salem R**, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. *J Vasc Interv Radiol* 2006; **17**: 1251-1278 [PMID: 16923973 DOI: 10.1097/01.RVI.0000233785.75257.9A]
- 12 **Lau WY**, Kennedy AS, Kim YH, Lai HK, Lee RC, Leung TW, Liu CS, Salem R, Sangro B, Shuter B, Wang SC. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. *Int J Radiat Oncol Biol Phys* 2012; **82**: 401-407 [PMID: 20950954 DOI: 10.1016/j.ijrobp.2010.08.015]
- 13 **Kennedy A**, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, Benson A, Espat J, Bilbao JI, Sharma RA, Thomas JP, Coldwell D. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys* 2007; **68**: 13-23 [PMID: 17448867 DOI: 10.1016/j.ijrobp.2006.11.060]
- 14 **Kennedy AS**, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, Garafalo M, Liu D, Coldwell D, Savin M, Jakobs T, Rose S, Warner R, Carter D, Sapareto S, Nag S, Gulec S, Calkins A, Gates VL, Salem R. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. *Int J Radiat Oncol Biol Phys* 2009; **74**: 1494-1500 [PMID: 19157721 DOI: 10.1016/j.ijrobp.2008.10.005]
- 15 **Ho S**, Lau WY, Leung TW, Chan M, Ngar YK, Johnson PJ, Li AK. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. *Eur J Nucl Med* 1996; **23**: 947-952 [PMID: 8753684 DOI: 10.1007/BF01084369]
- 16 **Gulec SA**, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRDOSE equations for dose calculations. *J Nucl Med* 2006; **47**: 1209-1211 [PMID: 16818957]
- 17 **Ho S**, Lau WY, Leung TW, Chan M, Johnson PJ, Li AK. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. *Eur J Nucl Med* 1997; **24**: 293-298 [PMID: 9143467 DOI: 10.1007/BF01728766]
- 18 **Lau WY**, Leung WT, Ho S, Leung NW, Chan M, Lin J, Metreweli C, Johnson P, Li AK. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. *Br J Cancer* 1994; **70**: 994-999 [PMID: 7947110 DOI: 10.1038/bjc.1994.436]
- 19 **Campbell AM**, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. *Phys Med Biol* 2001; **46**: 487-498 [PMID: 11229728 DOI: 10.1088/0031-9155/46/2/315]
- 20 **Martin RC**, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, Tatum C. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. *Cardiovasc Intervent Radiol* 2010; **33**: 960-966 [PMID: 20661569 DOI: 10.1007/s00270-010-9937-4]
- 21 **Fiorentini G**, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, Mambrini A, Montagnani F, Alessandrini P, Catalano V, Coschiera P. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. *Anticancer Res* 2012; **32**: 1387-1395 [PMID: 22493375]
- 22 **Tanis E**, Nordlinger B, Mauer M, Sorbye H, van Coevorden F, Gruenberger T, Schlag PM, Punt CJ, Ledermann J, Ruers TJ. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. *Eur J Cancer* 2014; **50**: 912-919 [PMID: 24411080 DOI: 10.1016/j.ejca.2013.12.008]
- 23 **Petrelli F**, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G, Barni S. Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol* 2017; **3**: 211-219 [PMID: 27787550 DOI: 10.1001/jamaoncol.2016.4227]
- 24 **Venook AP**, Niedzwiecki D, Innocenti F. Impact of Primary (1°) Tumor Location on Overall Survival (OS) and Progression-Free Survival (PFS) in Patients (Pts) with Metastatic Colorectal Cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). *J Clin Oncol* 2016; **34** [DOI: 10.1200/JCO.2016.34.15\_suppl.3504]
- 25 **Wasan HS**, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Peeters M, Findlay M, Weaver A, Mills J, Wilson C, Adams R, Francis A, Moschandreass J, Virdee PS, Dutton P, Love S, GebSKI V, Gray A; FOXFIRE trial investigators; SIFLOX trial investigators; SIFLOX-Glob trial investigators, van Hazel G, Sharma RA. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol* 2017; **18**: 1159-1171 [PMID: 28781171 DOI: 10.1016/S1470-2045(17)30457-6]
- 26 **Lee MS**, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. *J Natl Compr Canc Netw* 2017; **15**: 411-419 [PMID: 28275039 DOI: 10.6004/jncn.2017.0038]



Published By Baishideng Publishing Group Inc  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
Telephone: +1-925-2238242  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <https://www.f6publishing.com/helpdesk>  
<https://www.wjgnet.com>

